IMGO
NASDAQImago BioSciences Inc.
Latest news
25 items- PROmega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science CompaniesOmega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing
- 13D/GSEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)
- 13D/GSEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)
- 13D/GSEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)
- SECSEC Form 15-12G filed by Imago BioSciences Inc.15-12G - Imago BioSciences, Inc. (0001623715) (Filer)
- 13D/GSEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)
- SECSEC Form EFFECT filed by Imago BioSciences Inc.EFFECT - Imago BioSciences, Inc. (0001623715) (Filer)
- 13D/GSEC Form SC 13D/A filed by Imago BioSciences Inc. (Amendment)SC 13D/A - Imago BioSciences, Inc. (0001623715) (Subject)
- INSIDERSEC Form 4 filed by Keating Laurie4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- INSIDERSEC Form 4: Tapper Amy E. closing all direct ownership in the company4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- INSIDERSEC Form 4 filed by Kariuki Enoch4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- INSIDERSEC Form 4: Rienhoff Hugh Jr closing all direct ownership in the company4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- INSIDERSEC Form 4 filed by Eichorn Laura G.4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- INSIDERSEC Form 4: Henner Dennis closing all direct ownership in the company4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- INSIDERSEC Form 4: Arenberg Michael closing all direct ownership in the company4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- INSIDERSEC Form 4 filed by Chaya Moghrabi Dina4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- INSIDERSEC Form 4: Chiang Hsiangyi closing all direct ownership in the company4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- INSIDERSEC Form 4: Peppe Jennifer closing all direct ownership in the company4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- INSIDERSEC Form 4: Baltera Robert Jr. closing all direct ownership in the company4 - Imago BioSciences, Inc. (0001623715) (Issuer)
- SECSEC Form 25-NSE filed by Imago BioSciences Inc.25-NSE - Imago BioSciences, Inc. (0001623715) (Subject)
- SECSEC Form S-8 POS filed by Imago BioSciences Inc.S-8 POS - Imago BioSciences, Inc. (0001623715) (Filer)
- SECSEC Form S-8 POS filed by Imago BioSciences Inc.S-8 POS - Imago BioSciences, Inc. (0001623715) (Filer)
- SECSEC Form POS AM filed by Imago BioSciences Inc.POS AM - Imago BioSciences, Inc. (0001623715) (Filer)
- SECImago BioSciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits8-K - Imago BioSciences, Inc. (0001623715) (Filer)
- SECSEC Form SC 14D9/A filed by Imago BioSciences Inc. (Amendment)SC 14D9/A - Imago BioSciences, Inc. (0001623715) (Subject)
IMGO FAQ
7 questionsWhat does Imago BioSciences Inc. do?
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Where does IMGO stock trade?
Imago BioSciences Inc. (IMGO) is listed on NASDAQ.What sector and industry is IMGO in?
Imago BioSciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Imago BioSciences Inc. go public?
Imago BioSciences Inc. (IMGO) completed its IPO in 2021.What are analysts saying about IMGO?
Imago BioSciences Inc. has had 6 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $2500.00 price target on 2022-10-28. Recent price targets range from $2500.00 to $3700.00.What companies are similar to IMGO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IMGO side-by-side with any of them on Quantisnow.How can I track IMGO on Quantisnow?
Quantisnow aggregates Imago BioSciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMGO to receive live email and push alerts on every new disclosure.